[1]Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma-connecting aetiology, biology and therapy[J]. Nat Rev Endocrinol, 2017, 13(8):480-491.
[2]Liu Y, Huang N, Liao S, et al. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma[J]. Cell Prolif, 2021, 54(9):e13102.
[3]Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation[J]. Science, 2009, 324(5930):1029-1033.
[4]Chen XS, Li LY, Guan YD, et al. Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect[J]. Acta Pharmacol Sin, 2016, 37(8):1013-1019.
[5]Xie ShN, Kang Q, Zhang Y, et al. The Effects of over-expression of fructose-1,6-bisphosphatase 1 gene on reversing malignant biological behavior and inducing osteogenic differ-entiation of osteosarcoma cells[J]. Chinese Journal of Cell Biology, 2019, 41(12):2273-2281. (in Chinese)
谢圣男,康权,张遥,等.果糖-1,6-二磷酸酶1(FBP1)过表达对骨肉瘤细胞恶性逆转并向成骨分化的影响.中国细胞生物学学报[J].2019, 41(12):2273-2281.
[6]Pacold M, Brimacombe K, Chan S, et al. A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate[J]. Nat Chem Biol, 2016, 12(6):452-458.
[7]Samanta D, Park Y, Andrabi S, et al. PHGDH Expression is required for mitochondrial redox homeostasis, breast cancer stem cell maintenance, and lung metastasis[J]. Cancer Res, 2016, 76(15):4430-4442.
[8]Liu J, Zhang C, Wu H, et al. Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression[J]. J Clin Invest, 2020, 130(6):3253-3269.
[9]Wang C, Wan X, Yu T, et al. Acetylation stabilizes phosphoglycerate dehydrogenase by disrupting the Interaction of E3 ligase RNF5 to promote breast tumorigenesis[J]. Cell Rep, 2020, 32(6): 108021.
[10]Yang RL, Huang HM, Han CS, et al. Serine metabolism controls dental pulp stem cell aging by regulating the DNA methylation of p16[J]. J Dent Res, 2020, 100(1):90-97.
[11]Wei L, Lee D, Law C, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC[J]. Nat Commun, 2019, 10(1):4681.
[12]Song Z, Feng C, Lu Y, et al. PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer[J]. Gene, 2018, 642:43-50.
[13]Wu X, Xia J, Zhang J, et al. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma[J]. Br J Haematol, 2020, 190(1):52-66.
[14]Li Q, Qiu J, Yang H, et al. Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma[J]. Cancer Lett, 2020, 482:112-125.
[15]Viale A, Pettazzoni P, Lyssiotis CA, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function[J]. Nature, 2014, 514(7524):628-632.
[16]Murray PJ. On macrophage diversity and inflammatory metabolic timers[J]. Nat Rev Immunol, 2020, 20(2):89-90.
[17]Klomp L, de Koning T, MalingréH, et al. Molecular characterization of 3-phosphoglycerate dehydrogenase deficiency--a neurometabolic disorder associated with reduced L-serine biosynthesis[J]. Am J Hum Genet, 2000, 67(6):1389-1399.
[18]Locasale J, Grassian A, Melman T, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis[J]. Nat Genet, 2011, 43(9):869-874.
[19]Ma X, Li B, Liu J, et al. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E[J]. J Exp Clin Cancer Res, 2019, 38(1):66.
[20]Arlt B, Mastrobuoni G, Wuenschel J, et al. Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect[J]. J Enzyme Inhib Med Chem, 2021, 36(1):1282-1289.
[21]Rathore R, Caldwell KE, Schutt C, et al. Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma[J]. Cell Rep, 2021, 34(4):108678.
[22]Wagner ER, Luther G, Zhu G, et al. Defective osteogenic differentiation in the development of osteosarcoma[J]. Sarcoma, 2011, 2011:325238.
[23]Tang N, Song WX, Luo J, et al. Osteosarcoma development and stem cell differentiation[J]. Clin Orthop Relat Res, 2008, 466(9):2114-2130.
[24]Tan KO, Fu NY, Sukumaran SK, et al. MAP-1 is a mitochondrial effector of Bax[J]. Proc Natl Acad Sci USA, 2005, 102(41):14623-14628.
[25]Zhang ShJ, Effects of moderate intensity exercise on osteoporosis and bone morphogenetic protein 2 signaling pathway in ovariectomized rats[J]. Acta Anatomica Sinica,2020, 51(6):934-939. (in Chinese)
张帅军. 中等强度运动对去卵巢大鼠骨质疏松及骨形态发生蛋白2信号通路的影响[J], 解剖学报, 2020, 51(6):934-939.
[26]Cai M, Lin JL, Hou JM, et al. Differentiation of mesenchymal stem cells into osteoblasts and immunohistochemical identification[J]. Acta Anatomica Sinica, 2016, 47(5):628-632. (in Chinese)
蔡敏, 林建立, 侯建明, 等. 间充质干细胞的成骨细胞分化和免疫组织化学鉴定[J]. 解剖学报, 2016, 47(5):628-632.
|